Neuronetics (NASDAQ:STIM) Announces Quarterly Earnings Results, Misses Expectations By $0.07 EPS

Key Points

• Neuronetics reported a quarterly earnings per share (EPS) of ($0.15), missing expectations by ($0.07) EPS, while revenue reached $38.11 million, exceeding analyst estimates.
• The company's stock had a trading volume of 3,270,807 shares, significantly higher than its average of 1,186,601 shares, with a market cap of $308.14 million.
• Insider trading activity included EVP Stephen Furlong selling 193,460 shares, decreasing his ownership stake by 31.71%.

Neuronetics (NASDAQ:STIM - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.07), Zacks reports. Neuronetics had a negative return on equity of 174.15% and a negative net margin of 53.67%. The firm had revenue of $38.11 million for the quarter, compared to analysts' expectations of $36.80 million. Neuronetics updated its FY 2025 guidance to EPS and its Q3 2025 guidance to EPS.

Neuronetics Price Performance

STIM stock traded up $0.00 during mid-day trading on Tuesday, reaching $4.66. The company's stock had a trading volume of 3,270,807 shares, compared to its average volume of 1,186,601. The company has a current ratio of 2.44, a quick ratio of 2.28 and a debt-to-equity ratio of 1.40. The company's 50 day moving average is $3.80 and its two-hundred day moving average is $3.96. The stock has a market cap of $308.14 million, a PE ratio of -3.56 and a beta of 1.78. Neuronetics has a fifty-two week low of $0.52 and a fifty-two week high of $5.92.

Insider Activity at Neuronetics

In related news, EVP Stephen Furlong sold 193,460 shares of the firm's stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $4.27, for a total transaction of $826,074.20. Following the completion of the sale, the executive vice president directly owned 416,593 shares in the company, valued at approximately $1,778,852.11. This trade represents a 31.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 9.80% of the company's stock.

Institutional Investors Weigh In On Neuronetics

An institutional investor recently raised its position in Neuronetics stock. Goldman Sachs Group Inc. grew its stake in Neuronetics, Inc. (NASDAQ:STIM - Free Report) by 2,993.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 630,393 shares of the company's stock after buying an additional 610,014 shares during the period. Goldman Sachs Group Inc. owned 0.96% of Neuronetics worth $2,320,000 at the end of the most recent reporting period. Institutional investors own 53.59% of the company's stock.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.